Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Vaxneuvance by Year
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — International sales ($M) ($M)
Merck Vaxneuvance: $366M in FY2025, up 5.5% from a year earlier.
Latest, FY2025
366
Period ended Dec 31, 2025
Change on a year earlier
+5.5%
347 in FY2024
History
5 years
Since FY2021
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| Vaxneuvance | 825 | 808 | 2 | 459 | 461 | 0 | 366 | 347 | 5”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vaxneuvance (15-valent pneumococcal conjugate vaccine) — International sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 366 | +5.5% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 347 | +236.9% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 103 | +1,371.4% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 7 | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 0 | – | Form 10-K (filed 2024-02-26) ↗ |
Cite this data
StockData. (2026). Merck Vaxneuvance ($M), annual FY2021–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-vaxneuvance-intl
See every metric in the Merck KPI table. Data updated Oct 26, 2026.